XFOR
insider transactionsX4 Pharmaceuticals, Inc — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-17.0K
0 buy · 17.0K sell
Net value · 365d
-$72.8K
$0 in · $72.8K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
1
0 buy · 17.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
David Kirske KEY
Chief Financial Officer
$72.8K
17.0K sh · $4.29
Own -9%
-
Grant·A
Director
$0
110.0K sh
Own New
-
Grant·A
Director
$0
110.0K sh
Own New
-
Grant·A
Director
$0
110.0K sh
Own New
-
Grant·A
Director
$0
110.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 12, 2026 | David Kirske KEY | Sell S | 17.0K | $72.8K |
| Jan 1, 2026 | Francoise De Craecker | Grant A | 110.0K | $0 |
| Jan 1, 2026 | Michael S Wyzga | Grant A | 110.0K | $0 |
| Jan 1, 2026 | Murray Stewart | Grant A | 110.0K | $0 |
| Jan 1, 2026 | Gary Bridger | Grant A | 110.0K | $0 |
About XFOR insider trading
This page tracks insider transactions for X4 Pharmaceuticals, Inc (XFOR) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.